The in vitro diagnostics (IVD) market in Southeast Asia is forecast to grow steadily, with projections showing a 7% CAGR from 2025 to 2032 and an expected value of 4.11 billion US dollars by 2032. IVD tests, including PCR, ELISA, and next-generation sequencing, are becoming central to healthcare delivery by supporting early disease detection, chronic disease management, and better treatment decisions.
The rise of IVD is fueled by:
- A high prevalence of infectious and chronic diseases that demand reliable testing.
- Greater awareness of early diagnosis among patients and healthcare providers.
- Growing medical tourism, which strengthens investment in advanced healthcare services.
For IVD manufacturers, this creates both opportunities and challenges. While demand is expanding, barriers such as reliance on imported instruments, limited local manufacturing, and unequal access to diagnostics in rural areas remain significant.
To capture this growth, manufacturers need to adapt to local regulatory requirements, form regional partnerships, and design cost-effective solutions that meet the diverse needs of Southeast Asia’s healthcare systems.
If you’re navigating ASEAN’s evolving IVD landscape, these shifts raise important questions around access, regulation, and long-term strategy. Our regulatory specialists are always happy to unpack what this could mean for products and timelines.
Let’s exchange insights and explore what’s ahead.
Get in touch if you’d like to discuss how these shifts may affect products and timelines.
